{
    "organizations": [],
    "uuid": "54452a82999448cfe539f1145843feaa7bd45a13",
    "author": "",
    "url": "https://www.reuters.com/article/brief-shire-says-ema-has-validated-its-m/brief-shire-says-ema-has-validated-its-marketing-authorization-application-for-lanadelumab-idUSFWN1RA159",
    "ord_in_thread": 0,
    "title": "BRIEF-Shire ‍says EMA has validated its marketing authorization application for Lanadelumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 29, 2018 / 6:16 AM / Updated 5 minutes ago BRIEF-Shire ‍says EMA has validated its marketing authorization application for Lanadelumab Reuters Staff \n  Shire Plc: \n* ‍ANNOUNCED EUROPEAN MEDICINES AGENCY HAS VALIDATED ITS MARKETING AUTHORIZATION APPLICATION FOR LANADELUMAB (SHP643)​ \n* ‍REPORTS THAT HEALTH CANADA HAS COMPLETED SCREENING AND ACCEPTED NEW DRUG SUBMISSION UNDER PRIORITY REVIEW FOR INVESTIGATIONAL COMPOUND​ \n* ‍HEALTH CANADA’S RECENT ACCEPTANCE OF LANADELUMAB NDS FOR PRIORITY REVIEW SHORTENS REVIEW TIMELINE FROM 300 TO 180 DAYS​ Source text for Eikon: Further company coverage:",
    "published": "2018-03-29T09:16:00.000+03:00",
    "crawled": "2018-03-29T09:24:52.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "updated",
        "minute",
        "ago",
        "ema",
        "validated",
        "marketing",
        "authorization",
        "application",
        "lanadelumab",
        "reuters",
        "staff",
        "shire",
        "plc",
        "european",
        "medicine",
        "agency",
        "validated",
        "marketing",
        "authorization",
        "application",
        "lanadelumab",
        "shp643",
        "health",
        "canada",
        "completed",
        "screening",
        "accepted",
        "new",
        "drug",
        "submission",
        "priority",
        "review",
        "investigational",
        "canada",
        "recent",
        "acceptance",
        "lanadelumab",
        "nd",
        "priority",
        "review",
        "shortens",
        "review",
        "timeline",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}